Yet, at $2.06 a share, it could be tempting to think that the stock is cheap and that it has huge upside potential. Zomedica's ascent began in January of this year, when it announced the arrival of a new CEO, Robert Cohen. Zomedica Corp. Jun 16, 2020 6:05PM EDT. Everything is riding on veterinarians' acceptance of this new product… Its products would be competing against established names like IDEXX Laboratories (NASDAQ:IDXX) and Zoetis (NYSE:ZTS). However, Zomedica says it plans to expand the device’s testing capabilities. Dr. Morley is a trained veterinarian with instinctive business acumen. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the … 448. pinned by moderators. Zomedica Corp. News Releases. On the date of publication, Craig Adeyanju did not have (either directly or indirectly) any positions in the securities mentioned in this article. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. So which came first? ZOM shares newsflow has stalled, slowing the impetus in the stock. Lower costs and improved efficiency for veterinarians: If Truforma delivers on the promise of improved test accuracy, it could help veterinarians become more competitive in two ways. Zomedica partnered with semiconductor company Qorvo (NASDAQ:QRVO) to bring this tech to the point-of-care veterinary practice for the first time. Now, as a result, Zomedica says that it has over $90 million, net of all capital and operating expenditures from the fourth quarter. It's also still in-clinic, which means investing in the company early could potentially provide decent returns. However, the company expects sales will be robust over the next several years as it tries to create a TruForma instrument installed base. For more information, visit www.ZOMEDICA.com. Strong Competition: Surely, Zomedica would have plans to expand its product offerings over the next few years. You’ll have to wait and see. About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by … 69 comments. PDF Version . According to Zomedica, the technology’s high precision means veterinarians could diagnose companion animals for conditions such as thyroid and adrenal disorders without requiring a reference lab confirmation. This means that the standard extended process of diagnosing these ailments adds to the overall cost of treating cats and dogs. Shortly thereafter, Reddit traders piled into the stock , … Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. Simply put, more use cases increase the revenue opportunities for ZOM stock. Read full article. ZOM Stock: Pros and Cons of Buying Zomedica Ahead of Key Product Launch New tech for diagnosing dogs and cats could be a pet-care game changer, but uptake by vets isn't certain Nevertheless, it will be the first point-of-care instrument that can test the pancreas and proximal and distal small intestine for dogs and cats that are in distress. Zomedica is coming out with a lab testing product that veterinarians can use in their offices as opposed to sending it out to a lab for testing. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. Find the latest Zomedica Corp. (ZOM) stock quote, history, news and other vital information to help you with your stock trading and investing. Still, you shouldn’t arbitrarily have a high expectation that veterinarians would adopt the device quickly. ANN ARBOR, Mich., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it has signed an agreement with Miller Veterinary Supply (“Miller”) for the distribution of TRUFORMA™, Zomedica’s first product, planned to begin sales on March 30, 2021.